Viral gene therapy

Tomanin R, Scarpa M. 2004. Why do we need new gene therapy viral vectors Characteristics, limitations and future perspectives of viral vector transduction. Curr Gene Ther. 4 357-372. [Pg.251]

Potential risks Bacteria Yeast Insect cells Mammalian cells Transgenic animals Gene therapy viral vectors Cellular and gene therapy combination... [Pg.255]

Gene therapy is based on the concept that involves the treatment of defective gene in specific cell by either replacement or supplementing the genetic material in order to correct the defective one. Transfection efficacy covers many drawbacks in gene therapy. Viral or non-viral gene delivery systems are the two main types of vectors... [Pg.62]

Antisense Oligonucleotides. Table 2 Viral disorders with malignant complications as potential targets for ribozyme gene therapies... [Pg.188]

Viral vectors Gene transfer Gene therapy... [Pg.530]

Presently, 1,260 gene-therapy trials are underway worldwide (Tables 1 and 2). For details see http // www.wiley.co.uk/genetherapy/clinical/. Almost three fourths of all trials are based on viral vectors. The vast majority of nonviral gene-therapy trials use naked/ plasmid DNA (18% of all gene-therapy trials). [Pg.532]

An important safety issue of viral vectors is whether or not the recombinant viruses are able to replicate in the infected cells. Replication of viral vectors is unwanted in most gene-therapy approaches. Therefore, replication-defective vectors have been designed, which are able to perform only one initial infectious cycle within the target cell. In addition, replication-competent vectors have been designed, which are able to productively infect the target cell and to spread in the target tissue. [Pg.532]

Gene-therapy Vectors. Table 2 List of most common therapeutic genes used in gene-therapy trials (viral and non viral vectors)... [Pg.533]

A different antiviral approach uses intracellular expression of unmodified antisense molecules corresponding to viral sequences. Such an intracellular immunization approach may require a gene therapy protocol to deliver the antiviral transgene. In a phase I chnical trial, Levine et at. used intraceUularly expressed... [Pg.247]

Chronic Viral Infections as Targets for Antiviral Gene Therapy.268... [Pg.265]

Zhu Y, CuUen JM, Aldrich CE, SaputelU J, MiUer D, Seeger C, Mason WS, JUbert AR (2004) Adenovirus-based gene therapy during clevudine treatment of woodchucks chronically infected with woodchuck hepatitis virus. Virology 327 26 0 zu Putlitz J, Wieland S, Blum HE, Wands JR (1998) Antisense RNA complementary to hepatitis B virus specifically inhibits viral replication. Gastroenterology 115 702-713... [Pg.298]

Fig. 1.11 Applications of LDHs as (A) non-viral vector in gene therapy for transfection of DNA to the cell nucleus, and (B) as matrix for enzymes immobilization in the development of biosensors.

Miller, A.D., The problem with cationic liposome/micelle-based non-viral vector systems for gene therapy, Current Medicinal Chemistry, 2003, 10, 1195-1211. [Pg.15]

Li SD, Huang L (2006) Gene therapy progress and prospects non-viral gene therapy by systemic delivery. Gene Ther 13 1313-1319... [Pg.62]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...